Kidney drug study checks safety in sick and healthy volunteers

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Healthy Matched Control Participants Only (Cohort 2): * Stable renal function (for example, no clinically significant change in an estimated glomerular filtration rate (eGFR) within 3 months or longer prior to study the Screening Visit), as determined by the investigator. * Have an eGFR of ≥ 90 milliliter/minute/1.73m2 (mL/min/1.73m2) as determined via the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula without race. Renally Impaired Participants Only (Cohorts 1, 4 and 5) * Participants who have renal impairments. * Cohort 1 participants with severe renal impairment must have an eGFR ≥ 15 to \< 30 mL/min/1.73m2 not on dialysis. Cohort 1 should have at least 3 participants with eGFR ≤ 20 mL/min/1.73m2. * Cohort 4 participants with moderate renal impairment must have an eGFR of ≥ 30 to \< 60 mL/min/1.73m2. * Cohort 5 participants with mild renal impairment must have an eGFR of ≥ 60 to \< 90 mL/min/1.73m2. Cohort 3 * Participants with ESKD on IHD must have been on stable IHD for at least 3 months prior to Visit 1. * All renally impaired participants should be on stable standard of care for at least 4 weeks prior to Visit 1. All cohorts: * Body weight of at least 50 kilograms (kg) and body mass index (BMI) within the range ≥ 18 to ≤ 35 kg/m2, inclusive. * All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit. Exclusion Criteria: * History of QT prolongation associated with other medications that required discontinuation of that medication. * Congenital long QT syndrome. * Known history of primary immunodeficiency (congenital or acquired) or an underlying condition that predisposes to infection. * Concomitant immunosuppressive, steroid treatment. * Any clinically significant disease or disorder (eg, cardiovascular, pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal including bone fractures, endocrine including adrenal insufficiency, metabolic, malignant, psychiatric, major physical impairment) (Cohort 2). * Renal transplant participants, participants on dialysis, and those with a history of acute kidney injury (Cohorts 1, 4, 5). * Use of any of the prohibited medications in the 4 weeks prior to Visit 1 (Cohorts 1, 3, 4, 5). * Participants with a known hypersensitivity to AZD4144 or any of the excipients of the product.